Why so many significant phase III results in clinical trials?
View ORCID ProfileJérôme Adda, Christian Decker, View ORCID ProfileMarco Ottaviani
doi: https://doi.org/10.1101/19001495
Jérôme Adda
†Department of Economics and IGIER, Bocconi University, Via Roberto Sarfatti 25, 20136 Milan, Italy. Phone: +39–02–5836–5572. E-mail:
Christian Decker
‡Department of Economics, University of Zurich, Schönberggasse 1, 8001 Zurich, Switzerland. Phone: +41–44– 634–61–26. E-mail:
Marco Ottaviani
§Department of Economics and IGIER, Bocconi University, Via Roberto Sarfatti 25, 20136 Milan, Italy. Phone: +39–02–5836–3385. E-mail:

Posted November 25, 2019.
Why so many significant phase III results in clinical trials?
Jérôme Adda, Christian Decker, Marco Ottaviani
medRxiv 19001495; doi: https://doi.org/10.1101/19001495
Subject Area
Subject Areas
- Addiction Medicine (349)
- Allergy and Immunology (668)
- Allergy and Immunology (668)
- Anesthesia (181)
- Cardiovascular Medicine (2648)
- Dermatology (223)
- Emergency Medicine (399)
- Epidemiology (12228)
- Forensic Medicine (10)
- Gastroenterology (759)
- Genetic and Genomic Medicine (4103)
- Geriatric Medicine (387)
- Health Economics (680)
- Health Informatics (2657)
- Health Policy (1005)
- Hematology (363)
- HIV/AIDS (851)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (436)
- Neurology (3882)
- Nursing (209)
- Nutrition (577)
- Oncology (2030)
- Ophthalmology (585)
- Orthopedics (240)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1115)
- Primary Care Research (452)
- Public and Global Health (6527)
- Radiology and Imaging (1403)
- Respiratory Medicine (871)
- Rheumatology (409)
- Sports Medicine (342)
- Surgery (448)
- Toxicology (53)
- Transplantation (185)
- Urology (165)